Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease which engages most of the immune cells in its development. Various studies concerning the application of antibodies against TNF-α, BlyS, CD20, CD22, IL-6R and complement factors in treatment of SLE have been recently conducted and in spite of the good results reported by some of them, no defi nite conclusion on their risk-benefi t profi le can be drawn. The current review summarizes the results obtained in the fi eld and reveals the perspectives for the development of new and more effective strategies for SLE treatment in combination with other immunomodulating drugs.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease which involves most of the immune cells in its development. A variety of mechanisms implicated in its pathogenesis were established as apoptosis, formation of antibodies and immune response, which enables the creation of new therapeutic agents directed against specifi c targets. Recently, a number of studies on the application of different antibodies in the treatment of SLE were conducted. In spite of the good results reported by some of them, no defi nite conclusion on their risk-benefi t profi le can be drawn. The current review summarizes the results obtained in the fi eld until now.
Anti-TNF-α
TNF-α is a pleiotropic cytokine with both immunoregulatory and proinfl ammatory effects. It has been found to have higher levels in SLE patients compared with the levels in healthy controls, which correlated with the disease activity. 1 Adalimumab and infl iximab, anti-TNF-α monoclonal antibodies used in the therapy of psoriasis or other infl ammatory or autoimmune diseases, have been investigated in the therapy of SLE. In contrast, a case of subacute cutaneous lupus erythematosus occurring 2 to 3 weeks after subcutaneous administration of golimumab for rheumatoid arthritis was reported. 2 Other researchers have reported that etanercept, anti-TNF-α fusion protein, is relatively safe and long-term effective for refractory lupus arthritis 3 . Recently an open-label study has demonstrated that anti-TNF therapy could suppress local tissue destruction in SLE, but at the same time, the use of anti-TNF-α agents leads to the formation of autoantibodies, including autoantibodies to the double-stranded DNA (ds-DNA). Cardiolipin levels were also found to be increased. 4, 5 A possible mechanism of the TNF blocker-induced lupus could be related to a shift from apoptosis to necrosis, which results in the release of nuclear debris that trigger the production of ANA. There is evidence indicating that patients treated with TNF blockers, especially those with positive ANA, should be closely monitored for developing SLE. 6 Moreover, the induction of ANA or preexisting high-titer of ANA in TNF-treated patients is associated with the development of lupus and therefore TNF blockade is not advisable for this group of patients.
It is well known that all of the TNF-α inhibitors may induce lupus or lupus-like disease; however, the patient's risk level may differ from drug to drug. 2, 3 The reason could be the found in different apoptosis affection potential between the monoclonal antibodies and the fusion protein. 7 
Anti-BlyS
BlyS, also known as B cell activation factor, is a cytokine of the TNF ligand super-family that plays a key role in B lymphocyte differentiation, survival and activation. There is a defective regulation of BLyS in more than half of the SLE patients which is associated with higher BLyS serum levels that generally correlate with the anti-dsDNA concentration. 8 Belimumab is a fully human monoclonal antibody that specifi cally recognizes and inhibits the biological activity of BLyS. The mechanisms of action are not entirely clear. Belimumab recognizes and binds to BLyS, inhibits the stimulation of B cells, and restores the potential of the autoantibody-producing B cells to undergo the normal process of apoptosis. It reduces the number of the circulating B cells, but less deeply and durably than the anti-CD20 monoclonal antibodies. These characteristics of belimumab make it rationale for testing in patients with SLE.
Anti-CD20
The CD20 antigen is a membrane protein expressed on all mature B cells but not on plasma cells. Most lymphomas that develop in organ transplantation and in autoimmune diseases, including rheumatoid arthritis and SLE, are B-cell lymphomas.
Rituximab is very effective in depleting B cells from peripheral blood and moderately effective in clearing B cells from lymph nodes and bone marrow. The B cells depletion is rapid and may persist for 3 to 12 months. The Fab domain of rituximab binds to the CD20 antigen on B lymphocytes, and the Fc domain recruits immune effector functions to mediate B-cell lysis in vitro. A possible mechanism of cell lysis includes complement-dependent cytotoxicity, antibody-dependent-cell mediated cytotoxicity and stimulation of the apoptotic pathway. 9 The effect of rituximab on the circulating levels of auto-antibodies, which are presumably secreted by the mature plasma cells unaffected by the anti-CD20 antibody, is minor and rather inconsistent. Probably additional mechanisms of action operate, including memory cells depletion, abolition of antigen presentation by B cells and increased number of regulatory T cells. 10 Although rituximab is nonspecifi c for lupus antibodies a number of uncontrolled studies reported its effi cacy in some SLE patients, refractory to conventional treatments. 11 The most common adverse effects are related to its fi rst administration and consist in headache, nausea, urticaria and hyper-or hypotension. These reactions could be decreased by premedication with intravenous glucocorticoids. Rituximab is generally well tolerated when administrated alone or together with moderate doses of glucocorticoids or immunosuppressive agents, but it can render heavily immunosuppressed patients more susceptible to infection or severe neutropenia. However, the most serious complication is the progressive multifocal leukoencephalopathy probably caused by reactivation of the JC virus.
Veltuzumab and ocrelizumab, new anti-CD20 agents with modified structures are considered more effective than rituximab but the data are too limited. 12
Anti-CD22
CD22 is a trans-membrane glycoprotein, which specifi cally binds sialic acid with an immunoglobulin domain located at its N-terminus. The presence of this domain makes CD22 member of the immunoglobulin super-family. CD22 functions as an inhibitory receptor for B-cell receptor signaling and regulates B-cell migration and activity. There is a strict interaction between CD22 and CD19 -another regulator of B cell receptor signals. CD22 inhibits the CD19 phosphorylation via the tyrosine-phosphatase SHP-1, while CD19 regulates the CD22 phosphorylation by augmenting the Lyn kinase activity. This CD19/CD22 loop was found signifi cantly related to an autoimmune phenotype in mice 13 and appeared to be a potential therapeutic target for modulating B cell signaling in SLE.
Epratuzumab is a recombinant, humanized monoclonal antibody directed against CD22, which is present on mature B cells and on many types of malignant B cells. After binding to CD22, epratuzumab exhibits predominantly an antitumor activity which is most probably mediated through antibody-dependent cellular cytotoxicity.
Upon administration, the skin lesions, arthralgias, and central nervous system manifestations rapidly improved while cardiac and renal manifestations improved less rapidly. No signifi cant changes in T cells, immunoglobulins, or auto-antibody levels were observed. 14 However, there was a pronounced reduction in CD27-B cells and CD22-surface-expression on CD27-B cells, suggesting that these cells, which mainly comprise naïve and transitional B cells, are preferentially targeted by epratuzumab in vivo. The results indicate additional regulatory effects of the antibody by reducing the enhanced activation and proliferation of anti-immunoglobulin-stimulated lupus B cells after co-incubation with CD40L or CpG. Epratuzumab inhibited the proliferation of B cells from patients with SLE but not normal B cells under all culture conditions. 15 It is likely that in contrast to CD20 antibodies, epratuzumab functions more by modulation of B cells rather than by their depletion. 16 The encouraging initial fi ndings and the good safety profi le of epratuzumab make it promising for the treatment of SLE.
Anti-COMPLEMENT ANTIBODIES
Modulation of the complement system has been recognized as a promising strategy in drug discovery and a large number of therapeutic agents have been developed. There is evidence that the early complement proteins of the classic pathway C1q and C4 are protective and their absence predisposes to SLE, whereas the activation of the terminal components of the complement i.e. C5b-C9 is pro-infl ammatory and deleterious.
Eculizumab is a fully humanized monoclonal antibody directed against the complement protein C5. Its molecular weight is 148 kD. Eculizumab is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). The patients with that disease have a somatic genetic mutation in the X-linked gene PIG-A. That leads to the absence of a complement regulatory protein and to a generation of abnormal red blood cells that are defi cient in terminal complement inhibitors. By binding to C5, eculizumab inhibits its cleavage to C5a and C5b and prevents the generation of the infl ammatory terminal complement complex C5b-C9 which exerts hemolytic activity. 17 The mechanism of action of eculizumab makes it potentially attractive for the treatment of patients with lupus nephritis since the terminal components of the complement C5b-C9 play a role in infl ammation and podocytes and glomerular basement membrane damage. The role of eculizumab in SLE is still being studied.
Anti-IL-6R
Tocilizumab is a humanized anti-IL-6R monoclonal antibody approved for the treatment of rheumatoid arthritis. The possibility to use it for the treatment of other infl ammatory autoimmune diseases is still under investigation.
The blockade of the IL-6 receptor leads to a decrease in acute phase reactants and a decrease in immunoglobulin and anti-ds DNA antibodies, achieved probably by restoring the B-cells and Tcells homeostasis. Despite its effi cacy, there were signifi cant safety issues including bacterial keratitis and severe neutropenia which limits tocilizumab application in SLE. 18 
Anti-IL-1 RECEPTOR ANTAGONIST
Anakinra is a recombinant version of the human IL-1 receptor antagonist blocking the biological activity of IL-1. It is used for the treatment of severely active rheumatoid arthritis since it reduces arthritis, cartilage destruction, and bone resorption. IL-1 appeared involved in the etiology of glomerulonephritis in SLE which provides suffi cient potential evidence to introduce anakinra for the treatment of SLE.
A number of antibodies such as anti-IL-18, anti-IL-10 and anti-CD40L are also of interest but the data available are rather limited. 19 
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Anti-INFLAMMATORY PEPTIDES
H2A histone fragment, termed IIIM1 and alpha-1-antitrypsin fragment (UBE) have been investigated on mice models of SLE. 20 Both IIIM1 and UBE signifi cantly reduce proteinuria, serum IL17, IL12 and anti dsDNA antibodies in animals, making them potential target of investigations in future.
CONCLUSIONS
The development of monoclonal antibodies directed against specifi c targets is a relatively new addition to the pharmacologic armamentarium available for the treatment of SLE. Despite the promising results no fi rm conclusion on their risk-benefi t profi le can be drawn from the available preliminary data. The results obtained showed that some of the antibodies could fi nd application into the development of new and more effective strategies for SLE treatment after dose modifi cation or in combination with other immunomodulating drugs.
